Juliane

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Juliane

Quick Facts

Property Description
Active Ingredients Desogestrel and Ethinyl Estradiol
Form Oral Tablet
Pharmacological Class Hormonal Contraceptive (Estrogen/Progestin)
Common Use Prevention of Pregnancy (Contraception)
Origin Synthetic Hormones

What is Juliane?

Juliane is a prescription-only medication classified as a combined hormonal contraceptive (CHC) for systemic use, primarily functioning as a means of pregnancy prevention. It is an oral dosage form, administered as a tablet, and belongs to the pharmacological group of fixed-combinations of estrogens and progestins. This foundational identity differentiates it from alternative methods, such as progestin-only pills, by integrating two synthetic hormone types for systemic control. The formulation is clinically recognized for its effectiveness in offering predictable reproductive control to women of reproductive age.

What Type of Medicine is Juliane?

Juliane is a combination product composed of two distinct synthetic hormones formulated to suppress fertility in females of reproductive potential. The two active compounds are Desogestrel and Ethinyl Estradiol (EE). Juliane contains Ethinyl Estradiol, a synthetic estrogen, paired with Desogestrel, which is recognized as a third-generation progestogen. This chemical structure defines its classification within the group of hormonal contraceptives.

The specific action of this combination pill has been extensively studied, and the combination of these two hormone types is a reliable method for systemic reproductive control. The medication utilizes inert pharmaceutical excipients to deliver the active ingredients in a consistent, solid oral tablet form. Several comparable brands exist with this same Desogestrel/Ethinyl Estradiol composition, such as Apri, Mircette, and Ortho-Cept.

Primary Purpose: Systemic Pregnancy Prevention

The main purpose of Juliane is reliable contraception, achieved by establishing a comprehensive hormonal barrier. It operates by delivering these hormones systemically, which primarily leads to the inhibition of ovulation, preventing the monthly release of an egg from the ovaries. In addition to stopping ovulation, Juliane introduces two crucial supplementary actions: the hormones cause the cervical mucus to thicken, thereby impeding sperm movement into the uterus, and they modify the uterine lining (endometrium), making it unreceptive to implantation. This combined approach ensures systemic reproductive control, providing predictable pregnancy prevention.

What side effects are possible with Juliane?

Possible Side Effects and Safety Information

The safety profile of Juliane, a combined hormonal contraceptive, is structured by official regulatory documents, which classify potential reactions by system affected and severity. The most commonly reported events listed in regulatory documents include headache, nausea, breast tenderness, and changes in menstrual flow such as breakthrough bleeding and spotting. These effects are often most noticeable during the initial months of use.

Serious Adverse Reactions

The official labeling highlights the potential for rare but serious adverse reactions, primarily involving the Vascular System. These documented risks include Venous Thromboembolism (e.g., Deep Vein Thrombosis and Pulmonary Embolism), Arterial Thromboembolism (e.g., Stroke and Myocardial Infarction), and Hypertension. The risk of VTE is noted as being highest during the first year of use or when restarting the medication after a break of four weeks or more.

Safety concerns also extend to the Hepatobiliary System, with the potential for Hepatic Adenomas and Hepatocellular Carcinoma being documented in prescribing information.

Population-Specific Constraints

The regulatory profile defines specific constraints for use based on high-risk populations. The medication is generally inadvisable for women over 35 who smoke due to the significantly increased risk of serious cardiovascular events. Additionally, it is contraindicated in individuals with a history of thromboembolic disorders, severe liver disease, or known or suspected estrogen-dependent malignancies.

Overdose and Emergency Response

Juliane (Ethinyl Estradiol and Desogestrel) is an oral contraceptive and is not typically associated with the acute, life-threatening overdose scenarios seen with substances that cause respiratory depression, such as opioids. Serious complications from acute ingestion of multiple birth control pills are uncommon in adults. However, any overdose requires prompt medical assessment.

Potential Effects of Overdose

Ingestion of a large number of combined oral contraceptive pills may lead to side effects such as nausea, vomiting, and vaginal bleeding (withdrawal bleeding) which can occur shortly after stopping the drug or after a high-dose ingestion. Due to the estrogen component, there is a theoretical, though not well-documented, increased risk of thromboembolic events (blood clots) following a massive overdose, although this is usually more related to chronic use and individual risk factors.

When to Seek Help

Immediately contact emergency medical services (e.g., call 911 or your local emergency number) or a Poison Control Center if you or someone else has taken more than the prescribed dose of Juliane. Do not wait for symptoms to appear. While severe symptoms are rare, professional medical evaluation is essential to determine the extent of the ingestion and to monitor for any adverse effects, particularly in children or individuals with pre-existing conditions that increase the risk of blood clots. Provide the healthcare provider with the quantity ingested and the time of ingestion.

Therapeutic Uses of Juliane

What Juliane Treats: Main Uses and Benefits

The primary therapeutic use of Juliane, a combined hormonal contraceptive, is to provide systemic reproductive control that is considered relevant for pregnancy prevention for women of reproductive age. This medication is also commonly used to help with other conditions by regulating the menstrual cycle.

The medication is commonly applied to manage conditions characterized by cycle severity, including debilitating dysmenorrhea (severe menstrual pain), dysfunctional uterine bleeding (abnormally heavy or unpredictable flow), and acne vulgaris driven by systemic hormonal influences. The key benefit is that it helps manage cycle predictability, is relevant for pain reduction, and assists with maintaining functional stability.

“It is used for managing symptoms that interfere with daily functioning, supporting patients during episodes of heightened discomfort.”

The use of Juliane may also be part of symptomatic management that is associated with a reduction of risk for developing specific gynecological cancers, specifically against ovarian cancer and endometrial cancer.

Quick Fact: Relief for Cycle Severity
Symptom Category Symptoms related to heightened physiological activity and systemic imbalance.
Clinical Context Applied in scenarios requiring supportive symptom management of recurrent or episodic menstrual manifestations.
Patient Benefit Contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Juliane is a combined hormonal contraceptive indicated for use by women of reproductive age. Regulatory labeling defines strict population-based eligibility criteria, primarily centered on mitigating the risk of serious vascular events and the potential for exacerbating hormone-sensitive conditions.

Absolute Contraindications

The medicine is absolutely prohibited for use in populations where the risk is unacceptable. This includes:

  • Women over 35 years of age who smoke.
  • Current or history of thromboembolic disorders (e.g., DVT, PE), cerebrovascular disease, or coronary artery disease.
  • Known or suspected estrogen-dependent neoplasia, such as breast cancer or hepatic tumors.
  • Severe uncontrolled hypertension or diabetes mellitus with vascular involvement.
  • Migraine with focal neurological symptoms (aura).
  • Known or suspected pregnancy.

Restricted Use and Non-Eligibility

Use is not recommended for women who are breastfeeding in the immediate postpartum period. The medicine is not indicated for use in postmenopausal or elderly women. The label mandates discontinuation before and after major surgery or during periods of prolonged immobilization due to the increased thromboembolic risk. Furthermore, the use of the medicine is not established in patients with renal insufficiency, as formal studies have not been conducted in this population.

What should I know about interactions with other medicines?

Juliane’s interaction profile is primarily defined by the combined pharmacokinetic effects of its two active components and specific regulatory restrictions. Certain drug combinations are formally contraindicated due to the risk of severe outcomes documented in official government labeling. This includes co-administration with the Hepatitis C combination regimen containing Ombitasvir/Paritaprevir/Ritonavir, with or without Dasabuvir, due to the potential for elevated liver enzymes. A major restriction tied to a substance interaction is the strict prohibition of Juliane use in females over 35 years of age who smoke tobacco, due to a significantly increased risk of serious cardiovascular events.

The medication’s effectiveness may be altered by medicines that impact hepatic enzyme metabolism. Co-administration with strong or moderate CYP3A4 inducers (e.g., certain anticonvulsants) results in reduced clearance of the contraceptive hormones, leading to lower plasma concentrations and decreased exposure. Conversely, Juliane can inhibit CYP1A2, causing increased plasma concentrations and potential effects of co-administered drugs like Tizanidine or Caffeine.

Specific administration rules exist for certain interacting agents. When administered with Colesevelam, Juliane must be separated by four or more hours to minimize the documented reduction in hormone exposure. Furthermore, the combined hormonal contraceptive must be discontinued prior to starting the contraindicated Hepatitis C regimen and restarted approximately two weeks following completion.

Mechanism of Action

Juliane functions as an inhibitor of the Sodium-Glucose Cotransporter 2 ( SGLT2) protein, a transporter selectively expressed on the luminal membrane of epithelial cells in the proximal convoluted tubule of the nephron. SGLT2 is the primary biological target responsible for reabsorbing the majority of filtered glucose from the renal tubular fluid back into systemic circulation.

By non-competitive binding to SGLT2, Juliane reduces the functional capacity of this transporter, resulting in a dose-dependent decrease in renal glucose reabsorption. The molecular consequence is increased glucose and sodium concentration within the renal tubule, leading to elevated urinary excretion of both solutes (osmotic diuresis). Downstream, this solute delivery to the macula densa triggers a systemic-level physiological modulation: tubuloglomerular feedback. This mechanism reduces glomerular filtration rate and lowers intraglomerular pressure. Additional system-level effects include modest natriuresis and volume contraction.

Dosage and Administration Information

How Juliane is Used: Official Administration Guidelines

Juliane (Desogestrel/Ethinyl Estradiol) is a combined hormonal contraceptive that is administered exclusively via the oral route as a tablet.


Administration Schedule and Timing

Instruction Detail
Dosing Regimen One tablet is taken once daily according to a continuous, cyclic schedule of 28 days.
Cyclic Pattern The regimen typically involves 21 consecutive days of active (hormone-containing) tablets followed by 7 days of non-hormonal (placebo) tablets or a tablet-free interval.
Daily Consistency Each tablet must be taken at approximately the same time every day to maintain the necessary systemic hormone levels.
Intake Order The tablets must be consumed in the order directed on the blister packaging, which is essential for proper administration, particularly for multiphasic formulations.

Procedural and Population Rules

Treatment can be initiated on the first day (Day 1) of the menstrual cycle or on the first Sunday following the start of the period. For non-breastfeeding women postpartum, initiation is officially advised between 21 and 28 days after delivery. The standard dosing regimen is applied to postpubertal adolescents.

If a user is less than 12 hours late in taking an active tablet, the instruction is to take the tablet immediately. The administration protocol mandates that a new 28-day pack must be started immediately after the previous pack is completed, ensuring the total tablet-free period never exceeds 7 days.

Recent Clinical Evidence

Overview of Research Findings

Research on Juliane, a combination therapy, has explored its potential effects on two pathways associated with pain signals and inflammation. The evidence currently available includes findings from multiple clinical trials and subsequent systematic reviews, providing a summary of outcomes related to disease activity and safety.

Studies examined the effect of the drug on changes in function and reported symptom reduction in adult participants with the indicated condition. Research has also investigated the combination approach compared to single-drug therapy.


Key Trial Data Summary

The primary data on potential effectiveness come from a pivotal 12-week Phase 3 study involving 600 participants. Measurements in this trial included both Symptom Scoring (using established pain and inflammation scales) and Functional Outcomes (assessing changes in mobility).

Outcome Type Research Focus Key Finding Summary
Symptom Scores Changes in participant-reported pain and inflammation levels. Studies reported on the time frame during which participants first noted any changes after treatment initiation.
Functional Outcomes Assessment of joint mobility and physical activity levels. Researchers evaluated whether the drug was associated with changes in these markers.

Long-term data from a two-year extension period of the main trial reported on safety outcomes. Sub-studies also evaluated the drug's use in combination with physical therapy and outcomes for specific populations, including elderly participants and those with mildly impaired liver function.

Frequently Asked Questions (FAQ)

Common questions about Juliane (FAQ)

Q: Why do doctors prescribe Juliane instead of other options?

Juliane is defined in its official labeling by its components: the estrogen Ethinyl Estradiol and the progestogen Desogestrel. Regulatory documents state that Desogestrel is considered a third-generation progestogen. The selection of a specific combined oral contraceptive is typically based on its unique hormone combination and the balance of the individual patient’s risk factors.


Q: Does Juliane work immediately, or does it take a few weeks?

According to official patient information, the body requires an adjustment period before pregnancy is prevented. A second form of contraception, such as a barrier method, is advised for the first seven days of the first cycle of pills. Official guidance states this is necessary to ensure protection. After this initial period, the combined hormones should be working to prevent pregnancy.


Q: What happens if I forget to take Juliane for a day?

Missing one active pill (less than 48 hours late) is generally addressed by taking the missed pill as soon as it is remembered and then continuing the remaining pills at the usual time. If two or more active pills are missed, this is considered a high-risk scenario. Specific guidance for this situation involves the use of a backup barrier method for seven days and may require emergency contraception, depending on when in the cycle the doses were missed.


Q: How is Juliane different from [Name of similar drug]?

Juliane is a combination of the synthetic estrogen Ethinyl Estradiol and the progestin Desogestrel. The active metabolite of Desogestrel is etonogestrel, which is classified as a third-generation progestogen. Differences from similar oral contraceptives usually relate to the type of progestin used and the exact hormone dosage in the tablets.


Q: What are the most common reasons someone would stop using Juliane?

Regulatory adverse event lists indicate that common reactions can sometimes lead to stopping the medicine. These include bothersome, non-serious events like nausea, headache, breast tenderness, and irregular bleeding or spotting. Official documentation notes these effects are most noticeable during the initial months of use.


Q: Are there different versions or strengths of Juliane available?

Yes, Juliane is available under different brand names and generics that contain the same active ingredients. These formulations may be either monophasic (all active pills have the same hormone dose) or multiphasic (the doses change throughout the active portion of the cycle).


Q: Can Juliane affect my kidneys?

Official labeling notes that formal clinical studies on the use of Juliane have not been conducted in patients with renal insufficiency (impaired kidney function). Regulatory evidence indicates that the safety and effectiveness in this specific population are not fully established.


Q: Is it true that Juliane can cause weight gain or weight loss?

Official adverse reaction lists for this type of combined oral contraceptive include both weight increased and, less frequently, weight decreased as potential side effects. These are listed in the adverse reaction profile as potential effects.


Q: Will Juliane affect my energy levels during the day?

The drug's adverse reaction profile lists 'tired feeling' and 'weakness' as potential side effects. These entries indicate that some individuals taking this medication may experience a change in their energy levels.


Q: Does Juliane cause sleepiness or drowsiness?

Official adverse event information lists 'sleep problems' (insomnia) as a potential reaction associated with the medication. Drowsiness is not typically listed as a common central nervous system side effect.


Q: What should I do if I notice a change in my mood after starting Juliane?

Official safety data lists 'depressed mood' and 'mood altered' as common adverse events. Official guidance notes that persistent or significant changes in mood, or other serious symptoms of depression, warrant medical evaluation.


Q: Does Juliane interact with herbal supplements like St. John's Wort?

Yes, official warnings indicate that St. John's Wort is a strong enzyme inducer that can decrease the concentration of the contraceptive hormones in the blood. This interaction can decrease the effectiveness of Juliane, potentially leading to irregular bleeding and a risk of unintended pregnancy.


Q: Can Juliane change my appetite?

Official product information includes 'change in appetite' as a potential side effect. This means that an increase or decrease in appetite may occur while taking this type of medication.


Q: Is Juliane known to cause any skin reactions or rashes?

The official adverse reaction lists include common skin reactions such as rash and urticaria (hives). More serious skin conditions like erythema nodosum and erythema multiforme are also reported, though they are less common.


Q: Is it safe to drive or operate machinery while taking Juliane?

Regulatory documents list dizziness and visual changes as potential side effects. Due to the possibility of these effects, caution is generally indicated when performing tasks that require mental alertness, such as driving or operating machinery.


Q: How quickly does Juliane leave the body after the last dose?

According to the official pharmacokinetic data, the elimination half-life is approximately 27.8 hours for the active progestin (etonogestrel) and approximately 23.9 hours for the estrogen (ethinyl estradiol). The half-life refers to the time it takes for half of the drug to be eliminated from the bloodstream.


Q: What happens if I drink alcohol while taking Juliane?

Official interaction warnings indicate that the estrogen component of Juliane, Ethinyl Estradiol, may potentially increase the blood levels and central nervous system effects of alcohol. This means the effects of drinking alcohol may be more pronounced or unpredictable.


Q: Can Juliane interfere with lab test results?

Yes, regulatory documents note that combined oral contraceptives are known to alter the results of certain laboratory tests. These changes can affect tests related to liver function, thyroid binding, blood clotting factors (coagulation), and lipid (fat) profiles.


Q: Can I take Juliane if I am currently taking over-the-counter pain relievers?

Observational data suggests that combining hormonal contraceptives with nonsteroidal anti-inflammatory drugs (NSAIDs, such as ibuprofen or naproxen) may increase the risk of venous thromboembolism (VTE). Official summaries have noted the potential for this co-administration to further increase the VTE risk.


Q: Do I need to avoid any specific foods or drinks while taking Juliane?

Official interaction warnings state that grapefruit or grapefruit juice may increase the concentration of the hormones in the bloodstream, and their regular consumption is therefore generally not recommended.

How should Juliane be stored and disposed of?

Storage and Disposal Requirements for Juliane

Juliane (Desogestrel and Ethinyl Estradiol tablets) must be stored at controlled room temperature, specifically below 30^circC (86^circF), to maintain the product's stability and labeled shelf-life. The tablets must be protected from freezing, excessive heat, and moisture.

Official Storage and Handling Rules

The medicine should be kept in its original package and the container must remain tightly closed when not in use. This packaging integrity is necessary for optimal product protection. For safety, Juliane must be stored in a secure location, strictly out of the reach of children.

Disposal of Unused Product

Expired or unneeded tablets must not be discarded into household waste or wastewater. Disposal must be performed in accordance with local requirements for pharmaceutical waste to prevent environmental release, particularly avoiding contamination of aquatic life.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Juliane found in:

A-Z Index: